Sanford-Burnham to Partner with Pfizer
News Aug 20, 2013
The team will utilize novel screening tools including systems-biology approaches and technologies developed at the Institute with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes.
Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. The collaboration combines our expertise in fundamental disease biology and muscle metabolism with Pfizer’s expertise in drug discovery. Investigators will utilize the Conrad Prebys Center for Chemical Genomics to screen for new relevant targets using investigational compounds from Pfizer as well as evaluate compounds previously identified from the NIH chemical library. Once the screening identifies compounds of interest, Sanford-Burnham and Pfizer scientists will collaborate to characterize and further study the “hit” compounds to understand their mechanism of action. These compounds will then be used as “probes” to identify novel therapeutic targets for the treatment of diabetes.
Finding new medicines for diabetes
“Diabetes presents an enormous public health burden. There is an acute need to translate innovative science into potential new medicines for people living with this debilitating disease,” said Tim Rolph, Vice President and Head of Cardiovascular and Metabolic Diseases Research Unit at Pfizer. “Pfizer’s collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes.” Pfizer will have access to Sanford-Burnham’s team of world-class scientists and translational infrastructure dedicated to finding new approaches to targeting disease. Collaborating with researchers at a major pharmaceutical company will help us achieve our mission of translating high-impact science into new therapies. “This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem – complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research,” said Stephen Gardell, Ph.D., senior director of scientific resources in our Diabetes and Obesity Research Center.
Advancing drug discovery in the Prebys Center
The Prebys Center houses Sanford-Burnham’s state-of-the-art screening facility established to accelerate the rate of commercialization of basic research in an independent medical research setting. Our discovery capabilities include: ultra-high throughput screening, high-content screening, phenotypic screening, and target-deconvolution technologies. The Prebys Center is led and staffed by industry-trained professionals who work closely with Sanford-Burnham investigators and industry collaborators to translate scientific findings into actionable drug discovery projects.
Organizations looking to benefit from the artificial intelligence (AI) revolution should be cautious about putting all their eggs in one basket, a study published in Nature Machine Intelligence has found. Researchers found that contrary to conventional wisdom, there can be no exact method for deciding whether a given problem may be successfully solved by machine learning tools.READ MORE
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Have you ever been stressed out by the idea of doing math or statistics problems? You’re not alone. A new study has used a questionnaire and an analytical technique called "network science" to determine precisely what factors contribute to this kind of statistics anxiety among psychology majors.